Treating obstructive sleep apnea with hypoglossal nerve stimulation.

Area of Science:

• Neurology
• Sleep Medicine
• Biomedical Engineering

Background:

• Obstructive sleep apnea (OSA) is linked to reduced upper airway muscle activity during sleep.
• Hypoglossal nerve stimulation (HGNS) offers a potential therapeutic strategy to mitigate OSA.
• A novel HGNS system by Apnex Medical was investigated for OSA treatment.

Purpose of the Study:

• To evaluate the safety and efficacy of a new HGNS system for treating moderate to severe OSA.
• To assess the impact of HGNS on OSA severity, patient symptoms, and therapy compliance.

Main Methods:

• A prospective, single-arm interventional trial involving 21 patients with moderate to severe OSA intolerant to CPAP.
• Surgical implantation of the HGNS system.
• Polysomnography (PSG) to measure apnea-hypopnea index (AHI) at baseline and 6 months.
• Patient-reported outcomes including Epworth Sleepiness Scale (ESS), FOSQ, SAQLI, and BDI were assessed.

Main Results:

• HGNS was used on 89% of nights for an average of 5.8 hours.
• Significant improvements were observed in AHI (43.1 to 19.5), ESS (12.1 to 8.1), FOSQ (14.4 to 16.7), SAQLI (3.2 to 4.9), and BDI (15.8 to 9.7) at 6 months (P < 0.05).
• Two serious adverse events included infection and lead dislodgement.

Conclusions:

• The HGNS system demonstrated favorable safety, efficacy, and compliance in treating OSA.
• Patients experienced a significant reduction in OSA severity and related symptoms.
• HGNS presents a viable treatment option for OSA patients who cannot tolerate CPAP.